313 related articles for article (PubMed ID: 21209200)
1. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease.
Imam SZ; Zhou Q; Yamamoto A; Valente AJ; Ali SF; Bains M; Roberts JL; Kahle PJ; Clark RA; Li S
J Neurosci; 2011 Jan; 31(1):157-63. PubMed ID: 21209200
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function.
Ko HS; Lee Y; Shin JH; Karuppagounder SS; Gadad BS; Koleske AJ; Pletnikova O; Troncoso JC; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16691-6. PubMed ID: 20823226
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.
Imam SZ; Trickler W; Kimura S; Binienda ZK; Paule MG; Slikker W; Li S; Clark RA; Ali SF
PLoS One; 2013; 8(5):e65129. PubMed ID: 23741470
[TBL] [Abstract][Full Text] [Related]
4. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
Karuppagounder SS; Brahmachari S; Lee Y; Dawson VL; Dawson TM; Ko HS
Sci Rep; 2014 May; 4():4874. PubMed ID: 24786396
[TBL] [Abstract][Full Text] [Related]
5. Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.
Yasuda T; Hayakawa H; Nihira T; Ren YR; Nakata Y; Nagai M; Hattori N; Miyake K; Takada M; Shimada T; Mizuno Y; Mochizuki H
J Neuropathol Exp Neurol; 2011 Aug; 70(8):686-97. PubMed ID: 21760537
[TBL] [Abstract][Full Text] [Related]
6. STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.
Kurup PK; Xu J; Videira RA; Ononenyi C; Baltazar G; Lombroso PJ; Nairn AC
Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1202-7. PubMed ID: 25583483
[TBL] [Abstract][Full Text] [Related]
7. Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity.
Im E; Chung KC
J Neurochem; 2015 Aug; 134(4):756-68. PubMed ID: 25963095
[TBL] [Abstract][Full Text] [Related]
8. Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration.
Kim H; Shin JY; Jo A; Kim JH; Park S; Choi JY; Kang HC; Dawson VL; Dawson TM; Shin JH; Lee Y
Brain; 2021 Dec; 144(12):3674-3691. PubMed ID: 34581802
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.
Ko HS; von Coelln R; Sriram SR; Kim SW; Chung KK; Pletnikova O; Troncoso J; Johnson B; Saffary R; Goh EL; Song H; Park BJ; Kim MJ; Kim S; Dawson VL; Dawson TM
J Neurosci; 2005 Aug; 25(35):7968-78. PubMed ID: 16135753
[TBL] [Abstract][Full Text] [Related]
10. The c-Abl inhibitor in Parkinson disease.
Zhou ZH; Wu YF; Wang XM; Han YZ
Neurol Sci; 2017 Apr; 38(4):547-552. PubMed ID: 28078567
[TBL] [Abstract][Full Text] [Related]
11. The role of parkin in the differential susceptibility of tuberoinfundibular and nigrostriatal dopamine neurons to acute toxicant exposure.
Benskey MJ; Manfredsson FP; Lookingland KJ; Goudreau JL
Neurotoxicology; 2015 Jan; 46():1-11. PubMed ID: 25447324
[TBL] [Abstract][Full Text] [Related]
12. PICK1 inhibits the E3 ubiquitin ligase activity of Parkin and reduces its neuronal protective effect.
He J; Xia M; Yeung PKK; Li J; Li Z; Chung KK; Chung SK; Xia J
Proc Natl Acad Sci U S A; 2018 Jul; 115(30):E7193-E7201. PubMed ID: 29987020
[TBL] [Abstract][Full Text] [Related]
13. Parkin plays a role in sporadic Parkinson's disease.
Dawson TM; Dawson VL
Neurodegener Dis; 2014; 13(2-3):69-71. PubMed ID: 24029689
[TBL] [Abstract][Full Text] [Related]
14. Cooperative roles of c-Abl and Cdk5 in regulation of p53 in response to oxidative stress.
Lee JH; Jeong MW; Kim W; Choi YH; Kim KT
J Biol Chem; 2008 Jul; 283(28):19826-35. PubMed ID: 18490454
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Lin J; Sun T; Ji L; Deng W; Roth J; Minna J; Arlinghaus R
Oncogene; 2007 Oct; 26(49):6989-96. PubMed ID: 17486070
[TBL] [Abstract][Full Text] [Related]
16. miR-103a-3p regulates mitophagy in Parkinson's disease through Parkin/Ambra1 signaling.
Zhou J; Zhao Y; Li Z; Zhu M; Wang Z; Li Y; Xu T; Feng D; Zhang S; Tang F; Yao J
Pharmacol Res; 2020 Oct; 160():105197. PubMed ID: 32942015
[TBL] [Abstract][Full Text] [Related]
17. c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
Brahmachari S; Karuppagounder SS; Ge P; Lee S; Dawson VL; Dawson TM; Ko HS
J Parkinsons Dis; 2017; 7(4):589-601. PubMed ID: 29103051
[TBL] [Abstract][Full Text] [Related]
18. c-Abl mediates angiotensin II-induced apoptosis in podocytes.
Chen X; Ren Z; Liang W; Zha D; Liu Y; Chen C; Singhal PC; Ding G
J Mol Histol; 2013 Oct; 44(5):597-608. PubMed ID: 23515840
[TBL] [Abstract][Full Text] [Related]
19. Parkin is ubiquitinated by Nrdp1 and abrogates Nrdp1-induced oxidative stress.
Yu F; Zhou J
Neurosci Lett; 2008 Jul; 440(1):4-8. PubMed ID: 18541373
[TBL] [Abstract][Full Text] [Related]
20. c-Abl-p38α signaling plays an important role in MPTP-induced neuronal death.
Wu R; Chen H; Ma J; He Q; Huang Q; Liu Q; Li M; Yuan Z
Cell Death Differ; 2016 Mar; 23(3):542-52. PubMed ID: 26517532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
